Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Invivyd presented preclinical data on VMS063, its investigational monoclonal antibody for treatment and prevention of measles, at IDWeek 2026. VMS063 showed potent in vitro neutralization against contemporary measles genotypes B3 and D8, with a half-life-extended profile and intramuscular or subcutaneous delivery planned. The company has begun manufacturing scale-up toward clinical development in 2027, targeting an area with no FDA-approved treatments amid record U.S.
Key figures
- Drug Name
- VMS063
- Phase Of Trial
- Preclinical (clinical development planned 2027)
- Clinical entry year
- 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.